/
Oncology
Myelodysplastic Syndromes
50
Pipeline Programs↗
54
Active Trials↗
50
Companies Involved↗
Myelodysplastic Syndromes is a moderately active landscape with 50 programs across 50 companies. The most active players are Takeda, Otsuka, Bristol-Myers Squibb. 6 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical8
Phase 17
Phase 229
Phase 36
Approved
No programs
Analysis
Modality Breakdown
89%
Small molecule
42 of 47 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 47 classified programs, each share of the total. Modality classified for 98% of 50 pipeline programs.
Analysis
Trial Status
250
clinical trials
Completed114 · 46%
Terminated49 · 20%
Recruiting28 · 11%
Active, not recruiting17 · 7%
Unknown status17 · 7%
Withdrawn13 · 5%
Other12 · 5%
Clinical Trials
Trial Activity
250 trials
Page 1 of 17
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)